ADCT - ADC Therapeutics S.A.
NEXT EARNINGS:
Mar 26, 2026
(in 29 days)
EPS Est: $-0.32
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.50
DETAILS
HIGH:
$10.00
LOW:
$5.00
MEDIAN:
$7.50
CONSENSUS:
$7.50
UPSIDE:
70.84%
Market Cap:
543.82M
Volume:
742,697
Avg Volume:
1,149,325
52 Week Range:
1.05-4.8
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.95
Last Dividend:
$N/A
Exchange:
NYSE
Country:
CH
Employees:
263
IPO Date:
2020-05-18
EPS (TTM):
-1.62
P/E Ratio:
-1.22
Revenue (TTM):
70.84M
Total Assets:
321.98M
Total Debt:
123.00M
Cash & Equiv:
250.87M
Rev Growth (5Y):
97.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-43.9%
Debt/Equity:
-0.61
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.30 | $-0.40 | +25.0% | $16.4M | $21.6M | -23.8% |
| 2025-08-12 | $-0.50 | $-0.36 | -38.9% | $18.8M | $18.2M | +3.5% |
| 2025-05-14 | $-0.36 | $-0.38 | +5.3% | $23.0M | $17.5M | +31.3% |
| 2025-03-27 | $-0.29 | $-0.35 | +17.1% | $16.9M | $19.0M | -11.0% |
| 2024-11-07 | $-0.42 | $-0.36 | -16.7% | $18.5M | $18.8M | -2.0% |
| 2024-08-06 | $-0.38 | $-0.44 | +13.6% | $17.4M | $18.5M | -5.8% |
| 2024-05-06 | $-0.56 | $-0.56 | 0.0% | $18.1M | $18.1M | -0.3% |
| 2024-03-13 | $-1.03 | $-0.47 | -119.1% | $16.8M | $15.3M | +9.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 70.84M | 69.56M | 209.91M | 33.92M | 0 | 2.34M | 1.14M | 1.80M |
| Net Income | (157.85M) | (240.05M) | (157.13M) | (230.03M) | (246.29M) | (116.48M) | (123.10M) | (89.86M) |
| EPS | -1.62 | -2.94 | -1.99 | -3.00 | -3.77 | -1.74 | -2.29 | -1.53 |
| Total Assets | 321.98M | 354.78M | 490.86M | 617.97M | 513.69M | 137.68M | 150.56M | 271.95M |
| Total Debt | 123.00M | 124.38M | 129.85M | 139.70M | 115.08M | 5.03M | 0 | 0 |
| Cash & Equivalents | 250.87M | 278.60M | 326.44M | 466.54M | 439.19M | 115.55M | 138.81M | 262.75M |
| Operating Cash Flow | (123.83M) | (118.69M) | (138.31M) | (233.38M) | (168.73M) | (121.58M) | (121.36M) | (74.94M) |
| Free Cash Flow | (124.70M) | (121.90M) | (139.00M) | (239.75M) | (171.54M) | (123.73M) | (123.83M) | (78.10M) |
| FCF per Share | -1.28 | -1.49 | -1.78 | -3.12 | -2.62 | -1.85 | -2.30 | -1.33 |
| Book Value | (202.64M) | (148.25M) | 79.45M | 166.09M | 335.50M | 111.16M | 126.24M | 249.17M |
| Cash & ST Investments | 250.87M | 278.60M | 326.44M | 466.54M | 439.19M | 115.55M | 138.81M | 262.75M |
| ROC Equity | N/A | N/A | -1.98 | -1.38 | -0.73 | -1.05 | -0.98 | -0.36 |